流感季节+震荡市的防御属性，中药ETF(159647)获资金关注

Group 1 - The core viewpoint of the articles highlights the positive performance of the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 0.79% and specific stocks like Guangdong Wannianqing and Tailong Pharmaceutical showing significant gains [1] - The TCM sector is characterized as a defensive segment with both pharmaceutical and consumer attributes, showcasing a dividend advantage with the TCM ETF's 12-month dividend yield reaching 2.87% [1] - The peak flu season has arrived, with the H3N2 strain prevalent in Beijing, presenting opportunities for the TCM sector [1] Group 2 - The adjustment of the basic drug catalog is expected to continue, with a focus on opportunities for increasing TCM varieties [1] - The trend of declining prices for TCM materials is anticipated to lead to a recovery in gross margins, with optimism regarding the clearance of social inventories and innovation-driven growth [1] - The top ten weighted stocks in the Zhongzheng TCM Index account for 54.79% of the index, including major companies like Yunnan Baiyao and Tongrentang [2]